-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cannabidiol in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cannabidiol in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cannabidiol in Pain Drug Details:Cannabidiol is under development for the treatment of schizoprenia, neuropathic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-101 in Frontotemporal Dementia (FTD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-101 in Frontotemporal Dementia (FTD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.AL-101 in Frontotemporal Dementia (FTD)Drug Details:AL-101 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DSP-0390 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DSP-0390 in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.DSP-0390 in High-Grade GliomaDrug Details:DSP-0390 is under development for the treatment of solid...
-
Company Insights
Innovation and Patenting activity of Viridian Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Viridian Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Profile
Viridian Therapeutics Inc – Company Profile
Viridian Therapeutics Inc (Viridian), formerly Miragen Therapeutics Inc is a clinical stage biopharmaceutical company. The company discovers and develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. It focuses on thyroid eye disease and cardiovascular disease areas. It’s lead pipeline products candidates include VRDN-001 (Intravenous) for treating thyroid eye disease (TED); and VRDN-002 (Subcutaneous), an inhibitor using half-life technology for treating thyroid eye disease (TED). The company has been depending on the third...
Add to Basket -
Product Insights
Acute Myelocytic Leukemia (AML) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
AML Pipeline Products Market Report Overview Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the bloodstream and spread to the other parts of the body. Symptoms of AML include fatigue, fever, bleeding, breathing problems, and weight loss. The predisposing factors involved are exposed to...
-
Product Insights
Graves’ Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graves’ Ophthalmopathy Pipeline Drugs Market Report Overview Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves‘ ophthalmopathy. Symptoms include eye redness, inflammation, eyelid retraction, and weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery. The Graves’ Opththalmopathy pipeline drugs market research report provides comprehensive information on...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinitis Pigmentosa (Retinitis) Pipeline Drugs Market Report Overview Retinitis Pigmentosa (RP) refers to a group of diseases that cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa pipeline drugs market research report provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa, complete with analysis by stage of...
-
Product Insights
Wounds Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
A wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of diseases, such as leg ulcers or carcinomas. The Wounds pipeline drugs market research report provides comprehensive information on the therapeutics under development...